Ann: PEI provides constructive feedback for ph3 lung cancer trial, page-5

As long as Insight data holds true I believe they’ll be a chemo arm, particularly in PDL1 negative. Would be benchmarked against the classic PD-1/efti arm, as no patients in that group will get Keytruda alone. I’m anxious to see the trial design and first dose, but mostly anxious about TACTI-003 controlled topline data coming soon. I wonder if positive activity could be implied in NSCLC accelerating both indications. A Safe chemo free option is a serious unmet need, and the commercial manufacturing side of things is ready to launch with a likely partnership for distribution.